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Methods: One hundred twenty-one patients received up to seven intramuscular injections of
CAD106 (150 mg or 450 mg) or placebo 6 adjuvant over 60 weeks. An amyloid positron emission
tomography (PET) substudy was also conducted.
Results: CAD106 induced strong serological responses (amyloid-beta [Ab]–Immunoglobuline G
[IgG]) in 55.1% (150 mg) and 81.1% (450 mg) of patients (strong serological responders [SSRs]).
Serious adverse events (SAEs) were reported in 24.5% (95% confidence interval [CI] 16.7–33.8)
of the patients in the active treatment group and in 6.7% (95% CI 0.2–31.9) in the placebo group.
Three of the SAEs were classified as possibly related to study drug by the investigators. No evidence
of central nervous system inflammation was found. Amyloid-related imaging abnormalities (ARIAs)
occurred in six cases, all of them were strong serological responders. None of the ARIAs were symp-
tomatic. Serum Ab-IgG titer area under the curves correlated negatively with amyloid PET standard-
ized uptake value ratio percentage change from baseline to week 78 within the CAD106-treated
patients (r 5 20.84, P 5 .0004). Decrease in cortical gray-matter volume from baseline to week
78 was larger in SSRs than in controls (P 5 .0077).
Discussion: Repeated CAD106 administration was generally well tolerated. CAD106 450 mg with
alum adjuvant demonstrated the best balance between antibody response and tolerability.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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For 15 years, immunotherapy targeting amyloid-b (Ab)-
related proteins or protein fragments have been investigatedimer’s Association. This is an open access article under the CC BY-NC-ND
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disease (AD).
AN1792, the first active Ab immunotherapy tested in a
phase 2 clinical trial, demonstrated antibody responses in
mild-to-moderate AD [1]. However, this compound was dis-
continued because 6% of patients experienced meningoen-
cephalitis [2], likely caused by an Ab-specific T-cell
response (TH1-type CD4) [3]. Subsequent active and pas-
sive Ab immunotherapies have avoided this T-cell response
by using short or fragmented Ab peptides or peptide mi-
metics of the Ab N-terminus as B-cell epitopes [4–6].
Recently, two passive immunotherapies (monoclonal
antibodies), bapineuzumab and solanezumab, failed to
meet their primary end points in cognition and activities of
daily living (ADL) in phase-3 trials in patients with mild-
to-moderate AD [7,8]. Unlike passive immunotherapies,
active immunotherapies induce a more sustained
polyclonal Ab-specific response [6].
CAD106, a second-generation active Ab immunotherapy,
comprises multiple copies of the Ab1–6 peptide coupled to a
carrier containing 180 copies of bacteriophage Qb coat pro-
tein [9]. CAD106 effectively induced Ab antibodies in ani-
mal models, without activating an Ab-specific T-cell
response [10]. CAD106 doses up to 150 mg without adjuvant
induce consistent Ab-antibody responses in humans with no
major safety concerns [9].
This study evaluated the safety and tolerability profile of
CAD106 with and without adjuvant and determined the
optimal dosage level for future clinical studies. An explor-
atory substudy used amyloid positron emission tomography
(PET) imaging to assess antibody target engagement.2. Methods
2.1. Study design
This was a phase 2, 90-week, randomized, double-blind,
placebo-controlled, multicenter study (NCT01097096). Pa-
tients were centrally randomized into two semi-
overlapping cohorts across nine treatment groups with an
overall ratio of 7:1 CAD106 versus placebo (Fig. 1A).
In cohort 1, the effects of two adjuvants (alum [50 mg and
150 mg] and MF59 [squalene-based oil-in-water emulsion,
125 mL and 250 mL]) combined with CAD106 150 mg
were investigated. Cohort 2 was initiated after alum was
selected as adjuvant, based on cohort 1 data up to week
20. In cohort 2, CAD106 450 mg combined with alum
450 mg or without adjuvant versus placebo (alum 450 mg
only) was assessed. Patients received up to seven intramus-
cular injections of CAD106 (6adjuvant) or placebo (adju-
vant only) at weeks 0, 6, 12, 24, 36, 48, and 60. Patients
underwent a full evaluation at week 78 and were monitored
after treatment for safety up to 90 weeks.
The dose of CAD106 150 mg was identical to a dose used
without adjuvant in the phase 2a study [11]. The dose of
CAD106 450 mg was chosen because tripling of the dosewas previously shown to approximately double antibody ti-
ters [9]. Alum and MF59 were used as they both increased
antibody titers in animals.
Eligible patients aged ,85 years with mild AD (Mini–
Mental State Examination [MMSE] score: 20–26) diagnosed
according to the Diagnostic and Statistical Manual of Mental
Disorders version IV and National Institute of Neurological
and Communicative Disorders and Stroke and the Alz-
heimer’s Disease and Related Disorders Association criteria
were included. Full inclusion and exclusion criteria are pre-
sented in Supplementary Table 1. Exclusion criteria included
a history in the past 2 years of central nervous system (CNS)
inflammation and on screening, brain magnetic resonance im-
aging (MRI) of more than one or two microhemorrhages (de-
pending on the field strength). A discontinuation rule was
implemented a priori per protocol for patients on CAD106
who did not meet serological responder criteria following
the third injection. To maintain blinding, those receiving pla-
cebo were discontinued from study treatment in the same 7:1
ratio as the study randomization scheme. All patients pro-
vided written informed consent and the study was performed
in accordancewith the Declaration of Helsinki, Good Clinical
Practice standards, and local ethical requirements.2.2. Objectives
The primary objective was to assess the safety and toler-
ability of up to seven injections of CAD106 (150 mg or
450 mg) with or without adjuvant (alum or MF59) in patients
with mild AD over 90 weeks and to compare immunoge-
nicity of CAD106 across treatment arms.
Secondary objectives included characterization of the
antibody response; characterization of the Ab- and Qb-spe-
cific T-cell response in peripheral blood mononuclear cells
(PBMCs); and evaluation of the changes in cerebrospinal
fluid (CSF) biomarker levels (Ab1–40, Ab1–42, total-tau,
phospho-tau) over time.
Exploratory objectives included the effect on AD pro-
gression as measured by brain volumetric MRI and clinical
assessments. In addition, an amyloid PET substudy with
18F-florbetapir was conducted in cohort 2 to explore the ef-
fect of CAD106 on the 18F-florbetapir standardized uptake
value ratio (SUVR) over time.2.3. Assessments of primary outcome measures2.3.1. Safety and tolerability
An independent unblinded data monitoring committee
monitored safety data including adverse events, vital signs,
weight, electrocardiograms, and safety laboratory measure-
ments regularly throughout the study.
CNS markers for inflammation (cytosis, IgG, and oligo-
clonal bands) were assessed at screening, week 38, and
optionally at week 78. At screening and weeks 10, 20, 34,
50, and 78, fluid-attenuated inversion recovery, T2, T2*
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weighted brain MR sequences were acquired and read
centrally, in particular for amyloid-related imaging abnor-
malities (ARIAs) due to parenchymal vasogenic edema
(ARIA-E) or microhemorrhages or subarachnoid hemor-
rhage (ARIA-H).
Participants were instructed to record details of injection-
related reactions (local and systemic) in a diary for at least
7 days after each injection.
2.3.2. Ab-specific immune response
Ab- and Qb–Immunoglobuline G (IgG) titers were
measured in serum at screening and scheduled visits using
validated enzyme-linked immunosorbent assay (ELISA)
methods [9,11]. Titer levels were expressed in units relative
to a reference polyclonal serum. Testing of selected serum
samples indicated 10 units of Ab IgG to roughly correspond
to 1:100 in OD50. The lower limit of quantification (LLOQ)
was 8.93 units for Ab IgG and 1.04 units for Qb IgG [9].
Per protocol, patients treated with CAD106 were classi-
fied as serological responders (SRs), strong serological re-
sponders (SSRs), or serological nonresponders (NRs)
based on serum Ab-IgG titers based on the following a priori
definitions. The threshold for serological response was set to
16 units, based on the LLOQ of serum Ab-IgG titers plus 3
times the standard deviation (SD). SRs were defined as pa-
tients whose serum Ab-IgG titer was both .16 units be-
tween the second and the third injection and .26.8 units
(3*LLOQ) after the third injection. SSRs were defined as pa-
tients whose Ab-IgG titer was .35.7 units (4*LLOQ) after
2 different injections (not necessarily consecutive) starting
from the second injection onwards. The requirement to have
titers above the threshold at two distinct time-points enabled
responder definition to take into account also the persistence
of the antibody response. CAD106-treated patients who did
not fulfill the SR criteria were classified as NR.
2.4. Assessments of secondary outcome measures
The IFN-g ELISPOT assay has been developed to mea-
sure the Ab-specific T-cell response in human clinical trials
and to detect low-level responses [12]. T-cell responses to
the Ab1–6 and Ab1–42 peptides, and the Qb protein (positive
control) were centrally assessed at screening and week 8 in
PBMC samples. Every sample was stimulated with phytohe-
magglutinin as a positive control for cell viability, and in
addition, a study-independent Qb-positive PBMC control
sample was used at every run.
Levels of plasma Ab1–40 were measured using a meso
scale discovery (MSD)-based assay to assess the quality of
the produced Ab-specific IgGs [11].Fig. 1. (A) Study design and planned patient enrollment. (B) Patient disposition a
effect”: an insufficient immune response meeting nonresponder criteria as prespeci
Also includes two patients who discontinued treatment based on investigator’s decis
of immunizations. zOther 5 lost to follow-up, administrative problems, protocol
ation: PET, positron emission tomography.CSF samples were collected in all subjects at screening
and week 38, and optionally at week 78. Ab1–40 and Ab1–42
concentrations were determined centrally using an MSD-
based sandwich assay multiplex protein array platform,
and total tau and phospho-tau by ELISA (Innogenetics,
Belgium).2.5. Assessments of exploratory outcome measures
From the T1-weighted volumetric scans, the whole-brain
cerebral volume and hippocampal, cortical, and ventricular
volumes were determined using NeuroQuant software (Cor-
Techs Labs). For the PET substudy, 18F-florbetapir scans
(target injected activity 260 MBq) were performed at
screening, and weeks 40 and 78. Image analysis blinded to
treatment allocation was performed by Avid Radiopharma-
ceuticals Inc. using previously described methodology
[13]. The global cortical region (average of six regions) us-
ing the cerebellum as a reference region was used for inter-
pretation of results.
Changes in clinical status were assessed using Alz-
heimer’s Disease Assessment Scale–Cognitive Subscale
(including delayed recall), Alzheimer’s disease Cooperative
Study–Activities of Daily Living, Clinical Dementia Rating
scale, MMSE, and Neuropsychiatric Inventory Question-
naire. In addition, Category Fluency Test–animals,
Controlled Oral Word Association Test–letters, and
Computerized tests (CogState) were used (data not shown).2.6. Sample size
A total of 120 patients (cohort 1, n5 80; cohort 2, n5 40)
were planned to be enrolled, based on a sample size needed
to detect an increased risk of meningoencephalitis. The
probability of detecting 1 cases of meningoencephalitis
in patients was 98.7% across both cohorts, assuming a true
meningoencephalitis incidence rate of 6% as observed in
the AN1792 study [2].
In addition, the size of each individual treatment arm
(n 5 20) was chosen to detect differences in the mean area
under the curve (AUC) up to week 20 of Ab-IgG titers across
the treatment arms with each of the adjuvants in cohort 1.2.7. Randomization and masking
Eligible patients were randomized to one treatment arm
via an interactive voice response system. CAD106 and adju-
vant doses were prepared by an unblinded pharmacist and
administered by an unblinded study nurse. Patients, investi-
gators, and the site personnel were masked to the treatment
assigned.nd primary reasons for premature withdrawal. *“Unsatisfactory therapeutic
fied in the protocol and leading to discontinuation based on sponsor decision.
ion. y“Withdrawal of consent” attributedmainly to the temporary suspension
deviation. xIncludes the patient with subdural hemorrhage (SDH). Abbrevi-
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All analyses supporting the primary and secondary objec-
tives for tolerability, immunogenicity, antibody and T-cell
response, and safety were performed on the safety analysis
set (SAF), which consisted of patients who received 1 in-
jection of study medication and had1 post-injection safety
assessment. The full analysis set (FAS) consisted of all pa-
tients who received 1 injection of study medication and
had 1 post-injection antibody titer measurement. CSF bio-
markers and all exploratory objectives (e.g., volumetric
MRI, amyloid PET, and clinical scales) were analyzed based
on the biomarker positive analysis set (BPAS), which con-
sisted of patients who had baseline Ab1–42 in CSF ,500
pg/mL and, for patients in the PET substudy, PET SUVR
.1.1. One patient was excluded from the FAS and BPAS
due to a subdural hemorrhage which interfered with the as-
sessments.
The CAD106 dose groups were pooled across the adju-
vant and nonadjuvant treatment arms (CAD106 150 mg,
CAD106 450 mg, CAD106 total, placebo) for the reporting
of all primary safety assessments and secondary and explor-
atory outcomes. For Ab-IgG titers and injection-related re-
actions, data were summarized by the nine originally
assigned treatment arms. Ab-IgG titers were characterized
by the AUC for different time intervals depending on the
purpose of the analysis.
As per the a priori statistical plan, the main between-
group comparisons of exploratory measures were performed
between SSRs versus controls (placebo recipients plus
CAD106 NRs) based on the assumption that the response
to treatment would be driven by the serological response.
Exploratory variables were analyzed in the BPAS contrast-
ing SSRs to controls by a mixed-effects repeated-measures
model for the change or the percentage change from base-
line. In addition, where applicable, the relation to Ab-IgG ti-
ters (assessed by the AUC) from baseline to week 78 was
investigated using the Spearman correlation coefficient for
subjects treated with CAD106.3. Results
3.1. Patients
Between March 2010 and March 2011, 177 patients were
screened in 30 centers in 10 countries across Europe,
Switzerland, Canada, and the USA; 121 patients were ran-
domized (cohort 1, initiated in March 2010: n 5 79; cohort
2, initiated in January 2011: n 5 42). In total, 106 patients
received CAD106 (150 mg [n 5 69]; 450 mg [n 5 37]) and
15 patients received placebo (Fig. 1B).
In the CAD106 treatment group, 14 (13 %) patients were
actively discontinued from the study by the sponsor for not
meeting serological responder criteria. In the placebo group,
four patients (27%) were discontinued for the same reason to
maintain the blinding (Fig. 1B).All patients were included in the SAF. One patient ran-
domized to CAD106 450 mg was excluded from the pharma-
codynamic exploratory analyses because the imaging
end-points could not be evaluated due to subdural hemor-
rhage (SDH) as a result of head trauma followed by an intra-
cerebral hemorrhage (ICH) after surgical evacuation of the
SDH.
Demographic and baseline characteristics were broadly
similar across the CAD106 total and placebo groups
(Table 1). In patients who underwent pharmacogenetic
testing (101/121 patients), the majority in the CAD106 total
(69.8%) and placebo group (60.0%) were APOE ε4 carriers.3.2. Primary outcome measures3.2.1. Safety
All patients received one or more injection of CAD106 or
placebo, with the majority (79.2% CAD106 and 60.0% pla-
cebo) of patients receiving five or more of seven scheduled
injections. The study was put on temporary hold, and
CAD106 injections were suspended in all patients after a
case of SDH with ICH was reported (described previously).
After evaluation, it was concluded that this event was not
related to CAD106 and injections resumed after 2–6 months,
depending on country and site. Another two patients
(CAD106 150 mg, n 5 1; CAD106 450 mg, n 5 1) experi-
enced SDH associated with trauma.
Three deaths (malignant mesothelioma, n 5 1; laryngeal
cancer, n 5 1; pneumonia, n 5 1) were reported during the
study, all in the CAD106 total group (Table 2); none were as-
sessed as related to CAD106 by investigators.
Serious adverse events (SAEs) were reported in 24.5%
(95% confidence interval [CI] 16.7–33.8) of patients in the
CAD106 total group versus 6.7% (95% CI 0.2–31.9) for pla-
cebo (Supplementary Table 2).
Most of the SAEs were reported only in single subjects.
Three of the 26 SAEs in the CAD106 total group (allergic
dermatitis [immediately after the fourth injection], atrial
fibrillation [6 weeks after first injection], and acute psycho-
sis [14 weeks after seventh injection]) were deemed poten-
tially related to CAD106 by investigators.
The incidence of AEs was similar between the CAD106
total and placebo groups (83.0% vs. 80.0%). Most AEs
were mild to moderate in severity. The most commonly re-
ported AEs in the CAD106 total group (with large numerical
imbalances considering the 7:1 randomization ratio) were
headache, hypertension, and pyrexia (Table 2). AEs did
not appear to be CAD106 dose dependent.
Among the CAD106-treated patients, 10 discontinued
treatment (9.4% [4.6–16.7]) compared with none for pla-
cebo (0% [0.0–21.8]). Reasons for withdrawal were AEs
(n 5 7) or ARIA-H (n 5 4). None were assessed as being
related to CAD106 by the investigator except for one case
of ARIA-H and the case of atrial fibrillation (described pre-
viously).
Table 1
Patient demographic and baseline characteristics (SAF)
Characteristic CAD106 150 mg (n 5 69) CAD106 450 mg (n 5 37) CAD106 total (n 5 106) Placebo (n 5 15)
Sex, n (%)
Male 37 (53.6) 13 (35.1) 50 (47.2) 7 (46.7)
Female 32 (46.4) 24 (64.9) 56 (52.8) 8 (53.3)
Age, years
Mean (SD) 67.7 (9.0) 66.3 (9.4) 67.2 (9.1) 68.0 (8.4)
Age group, n (%)
,65 26 (37.7) 13 (35.1) 39 (36.8) 5 (33.3)
65–75 27 (39.1) 17 (45.9) 44 (41.5) 6 (40.0)
.75 16 (23.2) 7 (18.9) 23 (21.7) 4 (26.7)
Race, n (%)
Caucasian 67 (97.1) 37 (100.0) 104 (98.1) 14 (93.3)
Asian 1 (1.4) 0 1 (0.9) 1 (6.7)
Other 1 (1.4) 0 1 (0.9) 0
Years of education
Mean (SD) 12.3 (3.9) 12.4 (5.1) 12.3 (4.3) 12.9 (5.4)
Baseline MHIS, n (%)
0 37 (53.6) 25 (67.6) 62 (58.5) 8 (53.3)
1 25 (36.2) 11 (29.7) 36 (34.0) 6 (40.0)
2 6 (8.7) 0 6 (5.7) 1 (6.7)
3 1 (1.4) 1 (2.7) 2 (1.9) 0
Baseline MMSE
Mean (SD) 22.8 (2.2) 23.2 (2.2) 22.1 (2.2) 22.9 (1.9)
Time since first AD symptom was noticed by
patient/caregiver (years)
Mean (SD) 4.1 (2.6) 3.9 (2.2) 4.0 (2.5) 3.8 (3.5)
Median (range) 4 (1–12) 4 (1–10) 4 (1–12) 3 (1–15)
Time since first AD symptom was diagnosed
by physician (years)
Mean (SD) 1.6 (1.5) 1.5 (1.3) 1.6 (1.5) 1.9 (2.8)
Median (range) 1 (0–8) 1 (0–5) 1 (0–8) 1 (0–11)
APOE e4 carrier status, n (%)
Missing 8 12 20 0
Non ε4* 18 (29.5) 8 (32.0) 26 (30.2) 6 (40.0)
One ε4 allele* 29 (47.5) 15 (60.0) 44 (51.2) 5 (33.3)
Two ε4 alleles* 14 (23.0) 2 (8.0) 16 (18.6) 4 (26.7)
Abbreviations: SAF, safety analysis set; SD, standard deviation; MHIS, Modified Hachinski Ischemic Score; MMSE, Mini–Mental State Examination; AD,
Alzheimer’s disease; APOE ε4, apolipoprotein E ε4 allele.
*Percentage based on the number of patients genotyped.
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scheduled scans in six CAD106-treated patients, with
ARIA-H being confirmed in five patients in the CAD106
150 mg group and ARIA-E in a single patient on CAD106
450 mg (Table 2). All ARIA-H cases of more than two new
cerebral microhemorrhages and one case of subarachnoid
hemorrhage led to treatment discontinuation. ARIA-E was
initially observed at the scheduled MRI scan at week 36 in
a cortical location in a patient after the first three injections
of CAD106 450 mg without adjuvant (Supplementary
Fig. 1). Following spontaneous resolution, the patient
received the last two CAD106 450 mg injections at weeks
48 and 60 as per protocol, and the MRI finding did not reoc-
cur. All patients with ARIA-H or ARIA-E were asymptom-
atic and all were SSRs.
There were no symptoms or signs of CNS inflammation
as assessed by MRI or CSF parameters and no consistent
clinically relevant changes in vital signs, safety laboratory
measurements, and electrocardiogram parameters.The majority of patients reported, by diary, one or more
injection-related reactions (.73%) mostly in the CAD106-
treatment group (Supplementary Table 3). The highest inci-
dence of clinically relevant reactions, such as local reactions,
chills, myalgia, arthralgia, fatigue, and fever, was observed
in the CAD106 450 mg without adjuvant arm. The addition
of alum to CAD106 450 mg resulted in an unexpected
decrease in frequency of most injection-related systemic re-
actions compared with CAD106 450 mg without adjuvant
(Supplementary Table 3).
3.2.2. Immune response
Ab-IgG was not detected in serum at baseline or in
placebo-treated patients. Reproducible and sustained Ab-
IgG responses were observed following the second to the
seventh injections (Fig. 2A). Over the initial 20 weeks,
the median AUC of Ab-IgG titers increased by 1.86-fold
upon the 3-fold CAD106 dose increase from 150 mg to
450 mg (P 5 .0010). CAD106 induced a strong Ab-IgG
Table 2
Summary of adverse events and MRI findings (SAF)
n (%)
CAD106 150 mg
(n 5 69)
CAD106 450 mg
(n 5 37)
CAD106 total
(n 5 106)
Placebo
(n 5 15)
Summary of adverse events
Deaths* 2 (2.9) 1 (2.7) 3 (2.8) 0
SAEs 18 (26.1) 8 (21.6) 26 (24.5) 1 (6.7)
Discontinuations due to SAEs 3 (4.3) 2 (5.4) 5 (4.7)y 0
Discontinuations due to AEs 6 (8.7) 2 (5.4) 8 (7.5)z 0
Most frequent AEs (.10% of patients in
either treatment group)
Headache 10 (14.5) 7 (18.9) 17 (16.0) 1 (6.7)
Nasopharyngitis 10 (14.5) 6 (16.2) 16 (15.1) 2 (13.3)
Pyrexia 7 (10.1) 4 (10.8) 11 (10.4) 0
Hypertension 7 (10.1) 4 (10.8) 11 (10.4) 0
Back pain 7 (10.1) 3 (8.1) 10 (9.4) 0
Insomnia 7 (10.1) 2 (5.4) 9 (8.5) 0
Urinary tract infection 6 (8.7) 3 (8.1) 9 (8.5) 2 (13.3)
Fall 5 (7.2) 4 (10.8) 9 (8.5) 2 (13.3)
Depression 4 (5.8) 5 (13.5) 9 (8.5) 1 (6.7)
Fatigue 6 (8.7) 2 (5.4) 8 (7.5) 2 (13.3)
Osteoarthritis 7 (10.1) 0 7 (6.6) 0
Arthralgia 5 (7.2) 1 (2.7) 6 (5.7) 2 (13.3)
Aggression 4 (5.8) 1 (2.7) 5 (4.7) 2 (13.3)
Cough 3 (4.3) 2 (5.4) 5 (4.7) 2 (13.3)
Agitation 2 (2.9) 1 (2.7) 3 (2.8) 2 (13.3)
Anxiety 1 (1.4) 1 (2.7) 2 (1.9) 3 (20.0)
Decreased weight 1 (1.4) 0 1 (0.9) 2 (13.3)
Summary of MRI findings
ARIA-E 0 1 (2.7) 1 (0.9) 0
ARIA-H 5 (7.2) 0 5 (4.7) 0
2 microhemorrhages 4 (5.8)x 0 4 (3.8)x 0
Subarachnoid hemorrhage/superficial
hemosiderosis
1 (1.4) 0 1 (0.9) 0
Intraparenchymal hemorrhage 0 1 (2.7) 1 (0.9) 0
Epidural or subdural hemorrhagek 0 2 (5.4){ 2 (1.9) 0
Ischemic stroke 1 (1.4) 0 1 (0.9) 0
White-matter disease worsening 2 (2.9) 0 2 (1.9) 0
Abbreviations: MRI, magnetic resonance imaging; SAF, safety analysis set; SAE, serious adverse event; AE, adverse event; ARIA, amyloid-related imaging
abnormalities, with isolated vasogenic edema or sulcal effusions (ARIA-E)/with microhemorrhages or superficial hemosiderosis (ARIA-H).
*Two patients died soon after discontinuation due to SAEs (malignant mesothelioma due to chronic asbestosis and laryngeal carcinoma, respectively). In both
cases, the PI classified the SAE as unrelated.
yOne case each of atrial fibrillation (CAD106 150 mg), subdural hemorrhage (CAD106 450 mg), malignant mesothelioma (CAD106 150 mg), laryngeal cancer
(CAD106 450 mg), and lobar pneumonia (CAD106 150 mg). The latter three resulted in death.
zIn addition to the SAEs mentioned previously, the remaining AEs included one case each of ARIA-H, one case of aggression and irritability, and one case
with worsening of AD, all occurring in the CAD106 150 mg group.
xThree patients were discontinued from the study as per protocol with various reasons recorded (n5 1 due to amicrohemorrhage recorded as anAE, n5 1 due
tomicrohemorrhage as part of an abnormal test procedure [MRI], n5 1 withdrew consent). For one patient, themicrohemorrhages were detected retrospectively
at the end of the study during the data cleaning process.
kHemorrhage included subdural hematoma, epidural hematoma, subarachnoid hematoma, and parenchymal hemorrhage.
{Includes an SAE of subdural hemorrhage that resulted in study discontinuation and an SAE of subdural hematoma.
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150 mg and 450 mg doses, respectively, versus none on pla-
cebo (Fig. 2B). An increase in mean serum Qb IgG titers
was also observed with the higher dose (Supplementary
Fig. 2).
Neither of the adjuvants used in this study at any of the
dosages tested led to a significant increase in antibody titers.
Alum was selected for cohort 2 because the dose could be
further increased to 450 mg and was then shown, when added
to CAD106 450 mg, to improve tolerability (see
Supplementary Table 3).3.3. Secondary and exploratory outcome measures3.3.1. Characterization of the immune response
A two- to three-fold increase inmedian total plasmaAb1–40
levels was observed in the SSRs over time, whereas no
change was observed in controls (Fig. 2C). In the
CAD106 total group, a positive linear relationship between
plasma Ab1–40 levels and Ab-IgG titers was observed, for
example, at week 62, 2 weeks after the last injection
(r 5 0.79) (Fig. 3A).
Fig. 2. (A) Mean serum Ab-IgG titers (695% CI) by week (SAF); CAD106 150 mg group only includes patients who received the randomized dose of 150 mg
throughout the study and did not switch to the higher dose of 450 mg; X denotes the time of the injection. The apparent decline in titers from weeks 24–36 with
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to Ab1–6 or Ab1–42 peptides were not observed in either treat-
ment group. Using the Qb carrier peptide as positive control
for CAD106 immune response, the expected response
against the carrier peptide was observed after 8 weeks in
the actively treated group (Supplementary Table 4).
3.3.2. CNS biomarkers
A total of 26 patients from cohort 2 participated in the
amyloid PET substudy, of whom 20 (14 SSRs, and six con-
trols [three NRs and three placebo]; no patients were SRs)
were included in the BPAS for the PET substudy, with 15 pa-
tients (11 SSRs and four controls [two NRs and two pla-
cebo]) undergoing PET scans up to week 78.
The baseline mean (SD) SUVR of the composite cortical
region did not differ between SSRs and controls (11 SSRs,
1.47 [0.189] and four controls, 1.38 [0.192],
Supplementary Table 5).
A significant correlation between percentage change in
amyloid PET from baseline to week 78 and the AUC of
serum Ab-IgG titers was observed within the 13 (11 SSRs
and 2 NRs) CAD106 treated patients (r 5 20.84,
P 5 .0004). When the two placebo patients were included
(no serum Ab-IgG titers, AUC of 0), the correlation re-
mained significant (r 5 20.63, P 5 .0120; Fig. 3B). A lon-
gitudinal decrease in amyloid PET SUVR was observed in
SSRs but not in controls (mean percentage change [SD]
from baseline to week 78 was 21.23% [5.805%] for SSRs
and 11.44% [5.129%] for controls [Supplementary
Table 5]). Individual PET SUVRmeasures over time are pre-
sented according to the patients’ rank in terms of the AUC of
serumAb-IgG titers (Fig. 3C). A decrease of amyloid load in
the 30% of the SSRs with a high AUC was observed
compared to those with medium or low AUCs.
The volumetric MRI results indicated a larger percentage
decrease in cortical gray-matter volume from baseline to
week 78 in SSRs (n 5 41) versus controls (n 5 22;
P 5 .0077; Supplementary Table 6). The percentage change
from baseline did not correlate with the AUC of serum Ab
IgG (r520.20;P5.1456) (Supplementary Table 6). No sig-
nificant between-group differenceswere observed in the other
regions, that is, whole brain, hippocampus, and ventricles.
The longitudinal change in CSF biomarkers (phospho-
tau, total tau, Ab1–40, or Ab1–42) over the 78-week period
did not differ between the SSRs versus controls
(Supplementary Table 7).3.3.3. Clinical assessment
All clinical assessments worsened over time in all groups
indicating disease progression. No statistically significantCAD106 450 mg was attributed to the temporary suspension of immunizations wh
portion of patients meeting the responder criteria by CAD106 dose group (SAF)
strong serological responder (SSR). (C) Median and upper/lower quartile fold incre
(SDH) was excluded; controls include both placebo and NR. Abbreviations: Ab, am
set; SR, serological responder; SSR, strong serological responder.difference was observed between SSRs versus controls for
the change from baseline in any clinical scale (uncorrected
P . .05; BPAS, Supplementary Table 8). Numerically, the
decline in MMSE over 78 weeks was more pronounced in
the SSR group (24.93, n 5 39) than in the control group
(22.91, n 5 14), with a between-group difference at week
78 of 22.02 (95% CI 24.06, 0.02). Changes in clinical
scales did not correlate to AUC of serum Ab-IgG titers
(r,60.2). For instance, the correlation coefficient between
serum Ab-IgG titers and the MMSE change from baseline to
week 78 was r 5 20.11 (P 5 .4254).
Summary statistics for the FAS by treatment (CAD106
total and placebo) are presented in Supplementary
Tables 9–11.
4. Discussion
This phase 2 study in mild AD met both primary objec-
tives. CAD106 demonstrated an acceptable safety and toler-
ability profile, while evoking a strong serological response in
up to 81% of patients who received CAD106 450 mg.
CAD106 avoids activation of Ab-reactive T-cells by us-
ing a small N-terminal Ab1–6 peptide. No occurrences of
meningoencephalitis, autoimmune disease, CNS inflamma-
tion, or Ab-specific T-cell responses were observed. The
incidence of SAEs, headache, hypertension, and pyrexia
was higher in the CAD106 total group versus the placebo
group. SAEs in the placebo group (6.7%, 95% CI 0.2%,
31.9%) were less frequent than expected based on the inci-
dence observed in placebo groups from similar but much
larger trials (19.9% and 20.6% [7]). In contrast with previous
CAD106 studies, several cases of ARIA occurred in the
treated group, and these individuals had all developed a
strong serological response. Reports of ARIAmay be related
to the higher CAD106 dose (450 mg) or adjuvants used in the
present study compared to previous studies (CAD106 doses
of 50 and 150 mg without adjuvant), or the higher number of
subjects in this trial, all undergoing scheduled T2* MRI
sequence required to detect ARIA-H. All six cases were de-
tected at scheduled MRI scans and all were asymptomatic.
Patients with more than one or two (depending on MRI field
strength) microhemorrhages (a known risk factor for ARIA)
were excluded from the study, which may have limited new
treatment–emergent ARIA.
Reproducible and sustained antibody responses were
observed from the second injection in a dose-dependent
manner [9]. The antibody response was measured in units
in relation to a reference polyclonal rhesus serum, rather
than in titer units calculated based on serial dilutions of
tested samples as often done for other vaccines (such as
AN1792). The approach used in the current study alloweden the majority of patients missed the fourth injection in cohort 2. (B) Pro-
; includes serological nonresponder (NR), serological responder (SR), and
ase in total plasma Ab1–40, by visit (SAF); patient with subdural hemorrhage
yloid beta; CI, confidence interval; NR, nonresponder; SAF, safety analysis
Fig. 3. (A) Plasma Ab1–40 versus Ab-IgG titers at week 62; r5 0.63 for the total population. (B) Percentage change in PET global cortical SUVR versus AUC of
serum Ab-IgG titers up to week 78 for individual patients (BPAS); the data points show the 15 patients who received a longitudinal amyloid PET. Among those
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the course of CAD106 development. A direct comparison
of the immune response to that evoked by other vaccines
with respect to level of antibody titers or number of re-
sponders is not warranted as it does not take into account
the difference in the quality (e.g., epitopes, affinity, IgG sub-
types) of the induced antibodies. For CAD106, the serolog-
ical responder criteria were set with the aim to identify
subjects with persistent and high antibody response. Only
SSRs showed an increase in total plasma Ab1–40, an indica-
tor of peripheral biological activity of the antibodies. This
suggests that the criteria for defining the responder groups
were set appropriately.
Doubling of antibody titers was observed following an in-
crease of dose of CAD106 from 150 to 450 mg, but no in-
crease was seen following addition of either adjuvants
alum or MF59. However, tolerability was improved when
alum was added to CAD106 450 mg. Alum is well estab-
lished as an adjuvant in prophylactic vaccines with no
serious safety issues [14]. Based on tolerability and immu-
nogenicity, CAD106 450 mg with alum 450 mg was deemed
the best combination to induce optimal Ab-IgG titers with an
acceptable tolerability profile which led to the selection of
this CAD106 dose and adjuvant for future studies.
In an exploratory analysis in a subgroup of patients who
underwent 18F-florbetapir PET, the percentage change in
PET SUVR correlated inversely with Ab-IgG titers over
the 78-week period. However, a direct comparison between
the SSR and the NR/placebo groups did not yield a signifi-
cant difference. The difference between the correlational
and the categorical analysis can be explained by the wide
spread of antibody titers within the SSR group and the small
number of subjects in the NR/placebo group (n 5 4).
For the brain volumetric measures, a statistically signifi-
cant decrease in cortical gray-matter volumes was observed
in biomarker-positive SSRs versus controls. An apparent
decrease in brain volume has already been reported for
two other anti-amyloid immunotherapies, AN1792 [15]
and bapineuzumab [7]. The interpretation of the decrease
critically depends on whether it results from a volume reduc-
tion in the interstitial, neuronal, glial, or any other constitu-
ent. Although the antibody response against Ab correlated
with the decrease in amyloid load, there was no such relation
with the decrease in cerebral volume. Hence, the absence of
correlation makes a direct causal effect of the antibody
response unlikely. The changes in cortical volume in
CAD106 SSRs could theoretically have affected the longitu-
dinal measure of change in amyloid load (SUVR) but this
also requires further investigation.
Numerically, the decline in MMSE was larger in the
biomarker-positive SSRs compared to controls. However,who underwent longitudinal amyloid PET, therewere no SR cases. (C) Global corti
by serological responder groups (BPAS)*. The number on the plots indicates the r
amyloid beta; r, spearman correlation coefficient; AUC, area under the curve; BPAS
tomography; SSR, strong serological responder; SUVR, standardized uptake valuthis did not reach statistical significance and was not sup-
ported by results in any of the other clinical scales or corre-
lations to antibody titers. In addition, the small total sample
size, and specifically the small control group (n 5 14), and
the imbalance between the two groups implicate that the nu-
merical difference is of no significance. When the actively
treated group was compared to the placebo group in the
full analysis set, the longitudinal change in MMSE (23.5)
was identical between groups (Supplementary Table 11).
This phase 2 study has limitations. The study design was
complicated by the fact that the study was carried out in two
semi-overlapping cohorts, where CAD106 was administered
with or without an adjuvant (alum or MF59). Furthermore,
the study was put on a temporary clinical hold for
2–6 months due to the occurrence of one unrelated case of
intracerebral hemorrhage. This temporary hold has impacted
the dosing regimen for some patients in cohort 2 who did not
receive the fourth injection. Finally, patients who did not
develop a significant antibody response, as well as matching
placebo patients, were withdrawn from the study per proto-
col. All these factors render the results more difficult to inter-
pret. As a further limitation, amyloid PET SUVR, brain
volume, and clinical scale variables were exploratory end
points, not powered for significance or adjusted for multi-
plicity. The small sample size limits the sensitivity for de-
tecting a biological effect and prevents robust conclusions
from being made. However, the reduction of amyloid PET
SUVR observed in this study is consistent with CNS activity
for induced antibodies and the expected mode of action of
CAD106.
In conclusion, this phase 2 study met its primary objec-
tives: CAD106 elicited an Ab-specific immune response
with CNS activity and an acceptable safety profile. Amyloid
PET provided preliminary evidence suggestive of target
engagement. The relationship between CAD106-induced
Ab-IgG antibody titers and clinical efficacy needs to be
determined in larger studies, possibly targeting an earlier
stage of the disease.Acknowledgments
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1. Systematic review: We searched PubMed, with the
terms “Alzheimer,” “immunotherapy” or “immuni-
zation,” and “clinical trial.” The AN1792 trial was
aborted because of meningoencephalitis. The
CAD106 phase-1 and phase 2a studies showed
favorable safety and immunogenicity. A search of
clinicaltrials.gov yielded four other terminated
(ACC-001, AFFITOPE AD-02) or ongoing (ACI-24,
AF20513) active Ab immunization trials. Of the
passive Ab immunization trials in AD, none reached
primary efficacy end points.
2. Interpretation: The current phase 2b study had a
larger sample size and included a higher dose than
any of the previous CAD106 studies: the study drug
evoked a strong Ab-specific antibody response in a
dose-dependent manner in 55%–81% of patients.
Correlation between antibody response and longitu-
dinal change in amyloid load provides preliminary
evidence for target engagement.
3. Future directions: A larger-sized phase-3 trial in
earlier stages of the disease will evaluate potential
clinical benefit and replicability of effect on amyloid
load.
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